FDA Panel Votes Against Avastin For Breast Cancer Treatment
CBS Los Angeles (con't)
Affordable Care Act Updates: CBSLA.com/ACA
Health News & Information: CBSLA.com/Health
LOS ANGELES (CBS) — In a decision that could affect millions of women, a Food and Drug Administration advisory panel found that the best-selling cancer drug in the world should not be used on breast cancer patients.
The panel of cancer experts has ruled that Avastin should no longer be used in breast cancer patients, clearing the way for the government to remove its endorsement from the drug.
The vote is not binding, which means the FDA commissioner will make the final decision.
Doctors could still prescribe it for breast cancer patients, but most insurance companies would not cover the cost.
This is the second time an FDA panel has voted to stop Avastin for breast cancer treatment. The original vote was appealed by the company that produces it.
Many breast cancer patients who have used Avastin claim it has helped them.